...
首页> 外文期刊>Oncology letters >Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia
【24h】

Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia

机译:对急性白血病患者的D-二聚体和乳酸脱氢酶血浆水平的评价

获取原文
获取原文并翻译 | 示例
           

摘要

Despite the outstanding advances made over the past decade regarding our knowledge of acute leukemia (AL), relapsed AL remains to be associated with a dismal prognosis. A better understanding of AL relapse and monitoring of the D-dimer and lactate dehydrogenase (LDH) plasma levels following chemotherapy may aid clinicians in determining whether relapse may occur in the subsequent phases of the disease. The present study evaluated D-dimer and LDH levels in 204 patients with relapsed AL. Data were collected at the initial onset of AL, at complete remission (CR) and in patients with relapsed AL. D-dimer plasma levels were significantly increased in patients with initial AL and in patients with relapsed AL (P=0.005 and P=0.007, respectively) but not in those with CR. LDH levels were significantly increased in AL patients at the initial onset of disease and at relapse compared with patients achieving CR, irrespective of cell type. Plasma prothrombin time, activated partial thromboplastin time and fibrinogen levels were not significantly different across patients (with the exception of acute promyelocytic leukemia patients) at the initial onset, relapsed AL or CR. Routine hematological parameters (white blood cell count, hemoglobin, platelet count) were significantly different at the initial onset of AL (P=0.002, P<0.001 and P=0.001, respectively) and during relapsed AL (P=0.009, P=0.003 and P<0.001, respectively) compared with patients achieving CR, suggesting an association between D-dimer, LDH and relapsed AL. These results also indicate that determination of D-dimer and LDH levels may be useful for predicting the probability of relapse during chemotherapy, but should also be combined with routine hematological parameters.
机译:尽管过去十年的突出促进了我们对急性白血病(AL)的知识,但复发AL仍有与令人沮丧的预后相关。在化疗后,更好地理解Al复发和监测D-二聚体和乳酸脱氢酶(LDH)血浆水平可以帮助临床医生确定在疾病的后续阶段是否可能发生复发。本研究评估了204例复发患者的D-二聚体和LDH水平。在Al的初始发作,在完全缓解(Cr)和复发患者中收集数据。初始Al和患者的患者(P = 0.005和P = 0.007)患者,但不含C-患者,但不含D-二聚体血浆水平。与达到Cr的患者相比,在疾病初始发作和复发时,LDH水平显着增加,而无论细胞类型如何,都与患者进行复发。血浆凝血酶原时间,活化的部分血栓形成素时间和纤维蛋白原水平在初始发作时(急性早野血细胞白血病患者除外)没有显着差异,复发AL或CR。常规血液学参数(白细胞计数,血红蛋白,血小板计数)在Al的初始发作下显着不同(P = 0.002,P <0.001和P = 0.001)和在复发期间(P = 0.009,P = 0.003与达到Cr的患者相比,P <0.001分别相比,暗示D-二聚体,LDH和复发Al之间的关联。这些结果还表明D-二聚体和LDH水平的测定可用于预测化疗期间复发的概率,但也应与常规血液参数组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号